• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    2/14/23 4:45:47 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email
    SC 13G/A 1 tm236221d7_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    Relmada Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    75955J402

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 75955J402

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

    CUSIP No. 75955J402

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

    CUSIP No. 75955J402

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

    CUSIP No. 75955J402

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

           

     

     

     

    Item 1(a).Name of Issuer:

     

    Relmada Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    2222 Ponce de Leon, Floor 3 Coral Gables, FL 33134

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)  

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, $0.001 par value

     

    Item 2(e).CUSIP Number:

     

    75955J402

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount Beneficially Owned:
    See the response(s) to Item 9 on the attached cover page(s).

     

     

     

     

    (b) Percent of Class:
    See the response(s) to Item 11 on the attached cover page(s).
       
    (c) Number of shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:
    See the response(s) to Item 5 on the attached cover page(s).
         
      (ii) shared power to vote or to direct the vote
    See the response(s) to Item 6 on the attached cover page(s).
         
      (iii) sole power to dispose or to direct the disposition of
    See the response(s) to Item 7 on the attached cover page(s).
         
      (iv) shared power to dispose or to direct the disposition of
    See the response(s) to Item 8 on the attached cover page(s).

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:February 14, 2023

     

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Authorized Signatory

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC
    Its:General Partner

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Manager

     

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of February 14, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock $0.001 par value per share of Relmada Therapeutics, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Authorized Signatory

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC
    Its:General Partner

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Manager

     

     

     

    Get the next $RLMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    10/14/2022Buy → Neutral
    Guggenheim
    10/13/2022$64.00 → $7.00Outperform → Perform
    Oppenheimer
    12/20/2021$50.00 → $42.00Outperform
    SVB Leerink
    More analyst ratings

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

    6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous

    8/7/25 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, August 7, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13754263Webcast Access: Click Here A replay of the webc

    7/31/25 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

    Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa

    7/15/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    SEC Filings

    View All

    Relmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    8/7/25 5:01:15 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Relmada Therapeutics Inc.

    10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    8/7/25 4:06:03 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    7/23/25 4:30:45 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    5/20/25 6:03:44 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    5/20/25 6:03:12 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    5/20/25 6:02:33 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by CA and CO Ence Chuck

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    6/30/25 7:29:16 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Shenouda Maged

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    6/30/25 7:29:01 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Traversa Sergio

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    6/30/25 7:28:46 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously

    12/5/24 8:17:30 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously

    9/17/24 7:49:37 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously

    6/5/24 7:16:28 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    View All

    Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

    Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa

    7/15/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

    SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective June 25, 2025. Dr. Traversa currently serves as CEO of Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, where he has led the company through the advancement of multiple clinical-stage programs and financing events. "We're excited to welcome Sergio to the DIMERx team," said Nikhi

    7/9/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

    Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S. Pruthi, MD as Chief Medical Officer-Urology (CMO). Dr. Pruthi's expertise will be instrumental in the development of Relmada's lead program, NDV-01, for non-muscle invasive bladder cancer (NMIBC). The Com

    6/17/25 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Financials

    Live finance-specific insights

    View All

    Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

    6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous

    8/7/25 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, August 7, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13754263Webcast Access: Click Here A replay of the webc

    7/31/25 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advanci

    5/12/25 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    11/14/24 9:41:31 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    3/6/24 4:15:42 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/14/24 8:53:47 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care